138 related articles for article (PubMed ID: 15257046)
1. No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study.
ter Meulen CG; van Riemsdijk I; Hené RJ; Christiaans MH; Borm GF; Corstens FH; van Gelder T; Hilbrands LB; Weimar W; Hoitsma AJ
Transplantation; 2004 Jul; 78(1):101-6. PubMed ID: 15257046
[TBL] [Abstract][Full Text] [Related]
2. The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1st year after renal transplantation.
ter Meulen CG; Hilbrands LB; van den Bergh JP; Hermus AR; Hoitsma AJ
Osteoporos Int; 2005 Mar; 16(3):255-62. PubMed ID: 15232677
[TBL] [Abstract][Full Text] [Related]
3. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
Washburn K; Speeg KV; Esterl R; Cigarroa F; Pollack M; Tourtellot C; Maxwell P; Halff G
Transplantation; 2001 Nov; 72(10):1675-9. PubMed ID: 11726831
[TBL] [Abstract][Full Text] [Related]
4. The influence of early steroid withdrawal on body composition and bone mineral density in renal transplantation patients.
van den Ham EC; Kooman JP; Christiaans ML; van Hooff JP
Transpl Int; 2003 Feb; 16(2):82-7. PubMed ID: 12595969
[TBL] [Abstract][Full Text] [Related]
5. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
Stratta RJ; Alloway RR; Lo A; Hodge E
Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients.
Cole E; Landsberg D; Russell D; Zaltzman J; Kiberd B; Caravaggio C; Vasquez AR; Halloran P
Transplantation; 2001 Sep; 72(5):845-50. PubMed ID: 11571448
[TBL] [Abstract][Full Text] [Related]
7. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients.
Silverstein DM; Aviles DH; LeBlanc PM; Jung FF; Vehaskari VM
Pediatr Transplant; 2005 Oct; 9(5):589-97. PubMed ID: 16176415
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.
Westeel FP; Mazouz H; Ezaitouni F; Hottelart C; Ivan C; Fardellone P; Brazier M; El Esper I; Petit J; Achard JM; Pruna A; Fournier A
Kidney Int; 2000 Oct; 58(4):1788-96. PubMed ID: 11012914
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
[TBL] [Abstract][Full Text] [Related]
10. Clinical rejection and persistent immune regulation in kidney transplant patients.
Hendrikx TK; Klepper M; Ijzermans J; Weimar W; Baan CC
Transpl Immunol; 2009 Jul; 21(3):129-35. PubMed ID: 19398001
[TBL] [Abstract][Full Text] [Related]
11. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
[TBL] [Abstract][Full Text] [Related]
13. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study.
ter Meulen CG; van Riemsdijk I; Hené RJ; Christiaans MH; Borm GF; van Gelder T; Hilbrands LB; Weimar W; Hoitsma AJ
Am J Transplant; 2004 May; 4(5):803-10. PubMed ID: 15084178
[TBL] [Abstract][Full Text] [Related]
14. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
Sarwal MM; Yorgin PD; Alexander S; Millan MT; Belson A; Belanger N; Granucci L; Major C; Costaglio C; Sanchez J; Orlandi P; Salvatierra O
Transplantation; 2001 Jul; 72(1):13-21. PubMed ID: 11468528
[TBL] [Abstract][Full Text] [Related]
15. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
[TBL] [Abstract][Full Text] [Related]
16. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
[TBL] [Abstract][Full Text] [Related]
17. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
[TBL] [Abstract][Full Text] [Related]
18. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group.
Ahsan N; Hricik D; Matas A; Rose S; Tomlanovich S; Wilkinson A; Ewell M; McIntosh M; Stablein D; Hodge E
Transplantation; 1999 Dec; 68(12):1865-74. PubMed ID: 10628766
[TBL] [Abstract][Full Text] [Related]
19. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
